Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arvinas Holding Company ( (ARVN) ) has provided an announcement.
On October 20, 2025, Arvinas announced new patient-reported outcomes from its Phase 3 VERITAC-2 clinical trial for vepdegestrant, presented at the ESMO 2025 Congress. Vepdegestrant, developed with Pfizer, showed significant improvements in quality of life and delayed deterioration in patients with ESR1-mutated, ER+/HER2- advanced breast cancer compared to fulvestrant. The trial results reinforce vepdegestrant’s potential as a promising treatment option, highlighting its clinical benefits and supporting its development as a monotherapy for this patient group.
The most recent analyst rating on (ARVN) stock is a Sell with a $6.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas Holding Company’s overall stock score reflects significant financial challenges, including persistent losses and declining revenue, which weigh heavily on its valuation. While there is some technical strength and positive developments in clinical trials and partnerships, these are offset by financial restructuring and collaboration issues. Investors should be cautious, focusing on the company’s ability to improve its financial health and capitalize on its strategic initiatives.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform. The company targets debilitating and life-threatening diseases, with investigational drugs like vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin Lymphoma, ARV-102 for neurodegenerative disorders, and ARV-806 for mutated cancers. Arvinas is based in New Haven, Connecticut.
Average Trading Volume: 2,089,872
Technical Sentiment Signal: Hold
Current Market Cap: $698.9M
See more data about ARVN stock on TipRanks’ Stock Analysis page.